Doctors and nonprofit cancer organizations want Ohio legislators to pass a bill that would require insurance companies to cover biomarker testing for cancer, which is unaffordable to some patients.
Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss the clinical benefits reported with neratinib for the treatment of patients with HER2-positive early breast cancer.
Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss how standard-of-care treatment has evolved for patients with HER2-positive early breast cancer.